High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.

RAD 2025: Chovatiya toplines shifts in dosing strategies for topical, oral, and injectable AD therapy observed in both clinical trials and clinical practice.

Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.

Novel guidelines include specific strategies that support the prescription, implementation, and monitoring of lifestyle changes to reach glycemic control and, possibly, disease remission.

RAD 2025. Peter Lio, MD, shares details from his presentation on shared decision making when treating children with atopic dermatitis.

Both investigational vaccines induced strong immunity across all antigens and researchers reported no new safety signals, supporting phase 3 development.

RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.

Vaccination rates among US adults are roughly half that of pediatric populations, exposing older adults to risk for disease and complications, according to a new analysis.

RAD 2025: Chovatiya spoke at RAD about the need to better understand how treatments for AD are being used in the real world, after symptoms subside and skin signs clear.

A panelist discusses how shared decision-making between healthcare providers and patients should guide epinephrine device selection, with two real-world case studies demonstrating successful Neffy use in treating anaphylaxis with rapid symptom resolution.

A panelist discusses how Neffy addresses unmet needs through superior temperature stability (tolerating up to 122°F for 3-4 days), extended shelf life (24-30 months), and needle-free administration that eliminates injection-related complications.

A panelist discusses how real-world studies in Japan showed Neffy successfully treated grade 2 anaphylaxis symptoms in pediatric patients with a median resolution time of 16 minutes and minimal adverse effects.

A panelist discusses how FDA bracketing studies demonstrated that Neffy's pharmacokinetics and pharmacodynamics fall within the established safety and efficacy range of existing epinephrine auto-injectors, with rapid onset within one minute.

A panelist discusses how Neffy represents a novel intranasal epinephrine delivery system using three FDA-approved components: epinephrine, Intravail absorption enhancer, and a proven nasal spray device already used in other medications.

A panelist discusses how multiple barriers prevent timely epinephrine use, including patient reluctance to use auto-injectors, lack of device availability, uncertainty about administration timing, and cost concerns, leading to widespread underuse.

A panelist discusses how early epinephrine administration significantly reduces severe complications, prevents progression to life-threatening stages, and decreases the need for additional medical interventions like hospitalization or multiple doses.

A panelist discusses how epinephrine is the first and only evidence-based first-line treatment for anaphylaxis, working through alpha and beta adrenergic receptors to rapidly reverse life-threatening symptoms unlike slower-acting antihistamines.

A panelist discusses how anaphylaxis affects approximately 40 million people in the United States with severe systemic reactions involving multiple organ systems, leading to over 500,000 emergency room visits annually.

Arcutis Biotherapeutics announced today the enrollment of the first patient in the phase 2 INTEGUMENT-INFANT trial.

The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.

From primary care management of heavy menstrual bleeding to postpartum depression screening, find out what you may have missed at ACOG 2025.

The preventive monoclonal antibody is designed to protect infants against RSV infection through 5 months and is administered at the same dose, regardless of weight.

RAD 2025: As expert dermatologist Shahriari explains it, eczema may be just another rash on your schedule but for a patient, it could be the reason they don't leave the house.

RAD 2025: Explore expert insights on chronic hand eczema, its differences from atopic dermatitis, and emerging treatments in this informative video series.

RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.